GlassScriptPhysician profile
Jean Arroyo
NPI 1801336177
$10,614.82
in general payments reported to CMS, 2019-2025
30 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,609 · 2022: $2,295 · 2023: $2,311 · 2024: $1,901 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,701 · Education: $9.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,700.73 |
| Education | $9.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,489.96 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,420.73 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,208.88 | 2021-2025 | Fanapt, Hetlioz |
| Corium, LLC | $866.41 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $758.94 | 2021-2024 | Caplyta |
| Alkermes, INC. | $644.12 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Almatica Pharma LLC | $473.60 | 2021-2025 | Gralise, Loreev Xr |
| Avanir Pharmaceuticals, INC. | $430.53 | 2021-2022 | |
| Indivior INC. | $383.32 | 2021-2025 | Sublocade |
| Lundbeck LLC | $362.16 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $299.42 | 2021-2025 | Spravato |
| Neurocrine Biosciences, INC. | $296.39 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $281.22 | 2022-2025 | Auvelity, Sunosi |
| Eisai INC. | $263.17 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.84 | 2021-2025 | Trintellix |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $203.77 | 2023-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $159.48 | 2021-2025 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $154.28 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $118.02 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $114.65 | 2022-2024 | Jornay Pm |
| Braeburn INC. | $93.63 | 2024-2025 | Brixadi |
| Neos Therapeutics, LP | $93.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $78.20 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $43.69 | 2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $41.63 | 2025 | Jornay Pm |
| Harmony Biosciences LLC | $40.08 | 2025 | |
| Tris Pharma INC | $31.49 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $20.77 | 2023 | Qelbree |
| Validus Pharmaceuticals LLC | $16.25 | 2023 | Equetro |
| Vertical Pharmaceuticals, LLC | $15.10 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Arroyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.